Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) SVP Patrick R. O’neil sold 1,000 shares of the firm’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $58.35, for a total transaction of $58,350.00. Following the transaction, the senior vice president now directly owns 11,433 shares of the company’s stock, valued at $667,115.55. The sale was disclosed in a document filed with the SEC, which is available through this link.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) traded down $3.60 during trading on Friday, hitting $54.16. 1,778,812 shares of the stock were exchanged, compared to its average volume of 1,707,366. The company has a current ratio of 5.03, a quick ratio of 5.00 and a debt-to-equity ratio of 2.47. The company has a market capitalization of $6.44 billion, a P/E ratio of 246.76 and a beta of 2.90.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.03). Ionis Pharmaceuticals had a return on equity of 15.52% and a net margin of 5.25%. The business had revenue of $104.15 million during the quarter, compared to the consensus estimate of $93.29 million. During the same quarter in the previous year, the business posted ($0.47) earnings per share. The company’s quarterly revenue was up 170.7% compared to the same quarter last year. sell-side analysts expect that Ionis Pharmaceuticals, Inc. will post -0.13 earnings per share for the current fiscal year.

WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/11/03/ionis-pharmaceuticals-inc-ions-svp-patrick-r-oneil-sells-1000-shares.html.

Several brokerages have weighed in on IONS. Zacks Investment Research raised shares of Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $62.00 price objective for the company in a report on Friday, October 27th. Needham & Company LLC reissued a “buy” rating and set a $64.00 price objective on shares of Ionis Pharmaceuticals in a report on Tuesday, October 17th. Stifel Nicolaus reissued a “hold” rating and set a $50.00 price objective on shares of Ionis Pharmaceuticals in a report on Friday, October 13th. Goldman Sachs Group, Inc. (The) reissued a “sell” rating and set a $30.00 price objective on shares of Ionis Pharmaceuticals in a report on Friday, October 6th. Finally, BMO Capital Markets reissued an “outperform” rating and set a $69.00 price objective on shares of Ionis Pharmaceuticals in a report on Monday, October 2nd. Three research analysts have rated the stock with a sell rating, six have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $49.64.

A number of large investors have recently modified their holdings of the stock. Hanseatic Management Services Inc. lifted its position in Ionis Pharmaceuticals by 1.2% in the 2nd quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock valued at $177,000 after purchasing an additional 41 shares during the last quarter. Teacher Retirement System of Texas lifted its position in Ionis Pharmaceuticals by 0.4% in the 2nd quarter. Teacher Retirement System of Texas now owns 9,673 shares of the company’s stock valued at $492,000 after purchasing an additional 43 shares during the last quarter. Public Employees Retirement Association of Colorado lifted its position in Ionis Pharmaceuticals by 0.3% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 24,390 shares of the company’s stock valued at $1,241,000 after purchasing an additional 65 shares during the last quarter. World Asset Management Inc lifted its position in Ionis Pharmaceuticals by 3.4% in the 2nd quarter. World Asset Management Inc now owns 5,614 shares of the company’s stock valued at $286,000 after purchasing an additional 187 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in Ionis Pharmaceuticals by 9.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock valued at $190,000 after purchasing an additional 311 shares during the last quarter. Hedge funds and other institutional investors own 89.01% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.